
Canadians need safe and legally controlled access to psychedelic drug therapy including psilocybin-assisted therapy which, along with providing treatment for palliative patients, would provide opportunities for research and investment, says Michael Kydd, founder and principal of Kydder Group Inc., in an op-ed.